What Cytocell does

Cytocell is a product brand of Oxford Gene Technology IP Limited (OGT), a privately held UK-based molecular diagnostics company. It supplies a portfolio of over 545 fluorescence in situ hybridisation (FISH) DNA probes used by clinical and academic laboratories to detect chromosomal abnormalities and gene rearrangements in haematology, solid tumour, prenatal, microdeletion, rare disease, satellite enumeration, and subtelomere applications. The core technology binds fluorescently labelled probes to specific DNA sequences on chromosomes, enabling visualisation under fluorescence microscopy. Supporting the probe catalogue are the myProbes custom design service, IVDR-certified probes for EU regulatory compliance, a complementary FISH accessories line (pretreatment kits, buffers, hybridisation chambers, microscope filters, DAPI), and an Applied Spectral Imaging partnership for imaging and analysis. The wider OGT portfolio also includes SureSeq (NGS) and CytoSure (aCGH arrays), but CytoCell is the FISH-focused brand.

The business is run on a direct B2B sales-led model, with quotations handled individually and pricing not publicly disclosed. Customers are predominantly clinical cytogenetics, haematology, and pathology laboratories at hospitals, universities, and reference labs across the UK, USA, Canada, and select international markets (e.g., Serbia). Revenue is generated primarily through one-time consumable sales of FISH probes and accessories, with optional IVDR-certified variants for diagnostic use. The company invests in regulatory compliance (IVDR), customisation services, and customer support via technical and clinical specialists, but discloses no funding rounds, headcount, or revenue figures. No AI/ML capabilities are indicated.

Name

Cytocell

Legal name

Oxford Gene Technology IP Limited

Website

https://cytocell-us.com

Company type

Private

Operating status

Operating

Short description

Cytocell is the FISH probe brand of Oxford Gene Technology IP Limited, supplying over 545 fluorescence in situ hybridisation DNA probes and accessories to clinical and academic cytogenetics laboratories in the UK, USA, and Canada for haematology, solid tumour, prenatal, and rare disease applications.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Genetic, Cytogenetic & Prenatal Screening IVD (HLAHAAAI)

akta.pro secondary industries

Molecular Cytogenetics & Genomic Variation Services (Karyotyping/FISH/aCGH/CNV) (HLAGANAJ), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

Keywords

• FISH probes
• Cytogenetics diagnostics
• Molecular diagnostics
• DNA screening
• Cancer diagnostics

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. FISH Probes and Accessories: Sale of FISH probes for fluorescence in situ hybridisation applications, including IVDR-certified probes, haematology probes, solid tumour probes, prenatal probes, microdeletion probes, and FISH accessories such as tissue pretreatment kits, microscope filters, DAPI, hybridisation chambers, and buffers.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Cytocell manufactures and supplies fluorescence in situ hybridisation (FISH) probes and related reagents used by clinical and research laboratories to detect and localise DNA sequences on chromosomes. The portfolio includes over 545 probes covering haematology, solid tumour, prenatal, microdeletion, satellite enumeration, subtelomere, and rare disease applications, complemented by a custom probe design service (myProbes), IVDR-certified probes, FISH imaging/analysis solutions, and laboratory accessories.

Product overview

Cytocell offers a multi-product molecular diagnostics portfolio centered on fluorescence in situ hybridisation (FISH) technology. The core offering is the CytoCell FISH probe portfolio (over 545 probes) complemented by the myProbes customisation service for tailored probe design. The portfolio extends to IVDR-certified FISH probes for European regulatory compliance, FISH imaging and analysis solutions, and complementary platforms including SureSeq NGS for next-generation sequencing and CytoSure Arrays for aCGH genomic analysis. Supporting accessories and reagents round out the offering, enabling end-to-end cytogenetics workflows for haematology, solid tumour, prenatal, and rare disease applications.

Differentiator

Problem solved

Functional benefit

Brands

• CytoCell: World-leading fluorescence in situ hybridisation (FISH) product portfolio offering over 545 FISH probes for haematology, solid tumour, cytogenetics and rare disease applications
• CytoSure
• SureSeq
• myProbes

Products and services

• CytoCell FISH Probes

Quantifiable outcome

• Over 20 years of FISH product development experience
• +2 more outcomes

Named customers5 records

Segments7 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• CytoTest Inc. CytoTest develops and markets FISH probes and CGHaCGH arrays for clinical and research cytogenetics, closely overlapping with Cytocell's FISH and aCGH catalogue. Its custom probe design capabilities parallel Cytocell's myProbes service.
• Empire Genomics: Empire Genomics is a specialty FISH probe manufacturer with custom probe design services, directly comparable to Cytocell's catalogue and myProbes customisation offering. Both target haematology, solid tumour, and constitutional cytogenetics research and clinical labs.
• MetaSystems Group: MetaSystems manufactures FISH probes and automated imaging/capture systems for cytogenetics, directly competing with Cytocell's FISH probe portfolio and ASI imaging partnership. It serves the same haematology, solid tumour, and prenatal cytogenetics customer base globally.
• Abbott Molecular (Vysis): Abbott's Vysis brand is a long-established FISH probe line for oncology and prenatal genetic testing, competing head-to-head with Cytocell in clinical cytogenetics labs worldwide. Both companies supply FDA/IVDR-cleared FISH reagents to hospital and reference labs.

Broad incumbents

• Bio-Techne: Bio-Techne's diagnostics segment supplies FISH probes and reagents through its former Cytogen Haematology and prenatal franchises, competing with Cytocell's haematology and prenatal probes. As a diversified biotech tools and diagnostics company, it operates broader life sciences reagent lines alongside cytogenetics.
• Thermo Fisher Scientific: Thermo Fisher provides cytogenetics reagents, NGS oncology panels, and microarray solutions through its Life Sciences and Clinical Diagnostics divisions, meaning it competes with Cytocell's FISH, NGS, and arrays offerings. It is a broad incumbent serving the same clinical and research lab customers.
• Roche Diagnostics (Ventana): Roche offers in situ hybridisation reagents (including INFORM HER2 FISH) and broad IVD/companion diagnostics, overlapping with Cytocell's solid tumour FISH probes. Its scale, regulatory reach, and companion diagnostic partnerships make it a broad incumbent rather than a FISH-focused peer.
• Revvity (formerly PerkinElmer Life Sciences): Revvity sells molecular diagnostics reagents, FISH imaging systems, and cytogenetics software to clinical labs, overlapping with Cytocell's probe and imaging offerings. Its broader portfolio includes newborn screening and life sciences reagents, making it a broad incumbent rather than a FISH pure-play.
• Agilent Technologies (Cytogenomics): Agilent offers aCGH oligonucleotide arrays and cytogenomics software, directly competing with Cytocell's CytoSure aCGH product line. As a large life sciences instrumentation company, it overlaps with Cytocell's arrays franchise but does not focus on FISH probes.

Others

• Oxford Gene Technology (OGT) – sister product lines: OGT's SureSeq (NGS) and CytoSure (aCGH) product lines are sold alongside Cytocell within the same parent entity and share an overlapping salesforce and customer base. They are ecosystem/portfolio peers rather than competitors, sharing marketing and distribution infrastructure with the Cytocell FISH brand.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytocell